Victory Capital Management Inc Curis Inc Transaction History

Victory Capital Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	BUY	$0.51 - $0.78 $5,177 - $7,918	10,152 New	10,152 $6,000
Q2 2022 Aug 01, 2022	SELL	$0.71 - $2.43 $31,856 - $109,029	-44,868 Reduced 79.84%	11,330 $11,000
Q1 2022 May 04, 2022	SELL	$2.31 - $5.13 $63,873 - $141,849	-27,651 Reduced 32.98%	56,198 $51,000
Q4 2021 Feb 07, 2022	BUY	$4.45 - $8.09 $116,051 - $210,979	26,079 Added 45.14%	83,849 $399,000
Q3 2021 Nov 02, 2021	BUY	$6.94 - $8.85 $203,300 - $259,251	29,294 Added 102.87%	57,770 $452,000
Q2 2021 Aug 03, 2021	BUY	$7.45 - $16.27 $108,032 - $235,931	14,501 Added 103.76%	28,476 $230,000
Q1 2021 May 04, 2021	BUY	$8.78 - $12.8 $10,114 - $14,745	1,152 Added 8.98%	13,975 $158,000
Q4 2020 Feb 01, 2021	BUY	$1.08 - $8.2 $13,848 - $105,148	12,823 New	12,823 $105,000
Q2 2020 Aug 07, 2020	SELL	$0.63 - $1.7 $3,384 - $9,132	-5,372 Closed	0 $0
Q1 2020 May 04, 2020	BUY	$0.67 - $1.85 $288 - $797	431 Added 8.72%	5,372 $4,000
Q4 2019 Feb 04, 2020	SELL	$1.36 - $2.44 $43 - $78	-32 Reduced 0.64%	4,941 $8,000
Q3 2019 Nov 12, 2019	BUY	$1.74 - $2.83 $8,653 - $14,073	4,973 New	4,973 $11,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.